AVEO Pharmaceuticals, Inc. – NASDAQ:AVEO
Financial Health
0
1
2
3
4
5
6
7
8
9
Market closed
Open in 3 days
AVEO Pharmaceuticals stock price monthly change
+0.47%
month
AVEO Pharmaceuticals stock price quarterly change
+1.42%
quarter
AVEO Pharmaceuticals stock price yearly change
+322.54%
year
AVEO Pharmaceuticals key metrics
Market Cap | N/A |
Enterprise value | 480.55M |
P/E | -17.88 |
EV/Sales | 7.04 |
EV/EBITDA | -14.79 |
Price/Sales | 7.61 |
Price/Book | 18.00 |
PEG ratio | 0.35 |
EPS | -1.17 |
Revenue | 90.89M |
EBITDA | -32.47M |
Income | -40.52M |
Revenue Q/Q | 100.67% |
Revenue Y/Y | 255.97% |
Profit margin | -42.6% |
Oper. margin | -35.93% |
Gross margin | 83.14% |
EBIT margin | -35.93% |
EBITDA margin | -35.73% |
Sign up &
create your own Smart Feed
create your own Smart Feed
Personalize your watchlist with companies you want to keep track of and get notified in the smart feed every time fresh news arrives.
Sign up for freeAVEO Pharmaceuticals stock price history
AVEO Pharmaceuticals stock forecast
AVEO Pharmaceuticals financial statements
| Dec 2021 | 14.22M | -15.28M | -107.47% |
|---|---|---|---|
| Mar 2022 | 20.92M | -11.38M | -54.43% |
| Jun 2022 | 25.30M | -9.48M | -37.48% |
| Sep 2022 | 30.44M | -4.36M | -14.33% |
| 2022-05-05 | -0.25 | -0.3 |
|---|---|---|
| 2022-08-04 | -0.28 | -0.24 |
| 2022-11-07 | -0.18 | -0.09 |
| Dec 2021 | 105341000 | 59.47M | 56.46% |
|---|---|---|---|
| Mar 2022 | 98215000 | 61.27M | 62.39% |
| Jun 2022 | 98111000 | 67.52M | 68.82% |
| Sep 2022 | 101233000 | 72.38M | 71.51% |
| Dec 2021 | -12.18M | 8.36M | 5.52M |
|---|---|---|---|
| Mar 2022 | -8.21M | 11.52M | 0 |
| Jun 2022 | -2.45M | -1.78M | 561K |
| Sep 2022 | 194K | 7M | 36K |
AVEO Pharmaceuticals alternative data
| Aug 2023 | 114 |
|---|---|
| Sep 2023 | 114 |
| Oct 2023 | 114 |
| Nov 2023 | 114 |
| Dec 2023 | 114 |
| Jan 2024 | 114 |
| Feb 2024 | 114 |
| Apr 2024 | 114 |
| May 2024 | 114 |
| Jun 2024 | 114 |
| Jul 2024 | 114 |
AVEO Pharmaceuticals other data
41.09%
-3.78%
of AVEO is owned by hedge funds
14.12M
-1.29M
shares is hold by hedge funds
What is insider trading?
| Period | Buy | Sel |
|---|---|---|
| Aug 2021 | 2608 | 0 |
| Sep 2021 | 15000 | 0 |
| Transaction | Date | Insider | Security | Shares | Price per share | Total value | Source |
|---|---|---|---|---|---|---|---|
Option | BAILEY MICHAEL P director, officer.. | Stock Option (right to buy) | 164,525 | $3.67 | $603,807 | ||
Option | BAILEY MICHAEL P director, officer.. | Stock Option (right to buy) | 85,722 | $5.6 | $480,043 | ||
Option | BAILEY MICHAEL P director, officer.. | Stock Option (right to buy) | 26,499 | $6.2 | $164,294 | ||
Option | BAILEY MICHAEL P director, officer.. | Common Stock | 164,525 | $3.67 | $603,807 | ||
Option | BAILEY MICHAEL P director, officer.. | Common Stock | 85,722 | $5.6 | $480,043 | ||
Option | BAILEY MICHAEL P director, officer.. | Common Stock | 26,499 | $6.2 | $164,294 | ||
Purchase | BAILEY MICHAEL P director, officer.. | Common Stock | 15,000 | $6.48 | $97,200 | ||
Purchase | FERRARESSO MICHAEL | Common Stock | 2,608 | $5.75 | $14,996 | ||
Purchase | GROWTH EQUITY OPPORTUNITIES FUND IV, LLC 10 percent owner | Common Stock | 1,428,571 | N/A | N/A | ||
Purchase | BASKETT FOREST 10 percent owner | Common Stock | 1,428,571 | $5.25 | $7,499,998 |
| Patent |
|---|
Application Filling date: 14 Apr 2022 Issue date: 28 Jul 2022 |
Application Filling date: 7 Oct 2021 Issue date: 28 Jul 2022 |
Application Filling date: 5 Nov 2019 Issue date: 6 Jan 2022 |
Application Filling date: 13 Aug 2020 Issue date: 10 Jun 2021 |
Application Filling date: 19 Mar 2020 Issue date: 8 Apr 2021 |
Application Filling date: 29 Oct 2019 Issue date: 24 Sep 2020 |
Grant Utility: Anti-NOTCH3 antibodies Filling date: 8 Jan 2018 Issue date: 18 Aug 2020 |
Grant Utility: Anti-GDF15 antibodies Filling date: 20 Jul 2017 Issue date: 24 Mar 2020 |
Grant Utility: Anti-ERBB3 antibodies Filling date: 2 Mar 2017 Issue date: 3 Dec 2019 |
Application METHODS OF REVERSING CACHEXIA AND PROLONGING SURVIVAL COMPRISING ADMINISTERING A GDF15 MODULATOR AND AN ANTI-CANCER AGENT Filling date: 2 Nov 2018 Issue date: 26 Sep 2019 |
| Quarter | Transcript |
|---|---|
| Q2 2022 4 Aug 2022 | Q2 2022 Earnings Call Transcript |
| Q1 2022 5 May 2022 | Q1 2022 Earnings Call Transcript |
| Q4 2021 14 Mar 2022 | Q4 2021 Earnings Call Transcript |
| Q3 2021 8 Nov 2021 | Q3 2021 Earnings Call Transcript |
| Insider | Compensation |
|---|---|
| Mr. Michael P. Bailey (1965) Chief Executive Officer, Pres & Director | $1,080,000 |
Actinium: Overview Of A Promising Innovator
A Current Assessment On AVEO Pharmaceuticals
AVEO Pharmaceuticals Is Primed For A Breakout
AVEO Pharmaceuticals: Sticking To The Plan
AVEO Pharmaceuticals: Making Its Mark In Cancer Treatment
AVEO Oncology: Time To Be Patient
ASCO 2021: A Plethora Of Cancer Therapeutic Investment Ideas
-
When is AVEO Pharmaceuticals's next earnings date?
Unfortunately, AVEO Pharmaceuticals's (AVEO) next earnings date is currently unknown.
-
Does AVEO Pharmaceuticals pay dividends?
No, AVEO Pharmaceuticals does not pay dividends.
-
What is AVEO Pharmaceuticals's stock symbol?
AVEO Pharmaceuticals, Inc. is traded on the NASDAQ under the ticker symbol "AVEO".
-
What is AVEO Pharmaceuticals's primary industry?
Company operates in the Healthcare sector and Biotechnology industry.
-
How do i buy shares of AVEO Pharmaceuticals?
Shares of AVEO Pharmaceuticals can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include WeBull, Vanguard Brokerage Services, TD Ameritrade, E*TRADE, Robinhood, Fidelity, and Charles Schwab.
-
Who are AVEO Pharmaceuticals's key executives?
AVEO Pharmaceuticals's management team includes the following people:
- Mr. Michael P. Bailey Chief Executive Officer, Pres & Director(age: 60, pay: $1,080,000)
-
How many employees does AVEO Pharmaceuticals have?
As Jul 2024, AVEO Pharmaceuticals employs 114 workers.
-
When AVEO Pharmaceuticals went public?
AVEO Pharmaceuticals, Inc. is publicly traded company for more then 15 years since IPO on 12 Mar 2010.
-
What is AVEO Pharmaceuticals's official website?
The official website for AVEO Pharmaceuticals is aveooncology.com.
-
Where are AVEO Pharmaceuticals's headquarters?
AVEO Pharmaceuticals is headquartered at 30 Winter Street, Boston, MA.
-
How can i contact AVEO Pharmaceuticals?
AVEO Pharmaceuticals's mailing address is 30 Winter Street, Boston, MA and company can be reached via phone at 857 400 0101.
AVEO Pharmaceuticals company profile:
AVEO Pharmaceuticals, Inc.
aveooncology.comExchange:
NASDAQ
Full time employees:
114
Industry:
Biotechnology
Sector:
Healthcare
AVEO Pharmaceuticals, Inc., a biopharmaceutical company, focuses on developing and commercializing medicines for cancer patients. It markets its lead candidate, FOTIVDA, an oral, once-daily, vascular endothelial growth factor receptor tyrosine kinase inhibitor, which is used for the treatment of renal cell carcinoma (RCC); and tivozanib for the treatment of RCC, HCC, immunologically cold tumors, and CCA. The company has also completed a Phase II clinical trial of tivozanib in combination with Opdivo (nivolumab) for the treatment of RCC. In addition, it is developing Ficlatuzumab, a potent humanized immunoglobulin G1 (IgG1) monoclonal antibody that targets hepatocyte growth factor that is in a Phase II clinical trial for the treatment of squamous cell carcinoma of the head and neck, pancreatic cancer, and acute myeloid leukemia; AV-203, a potent humanized IgG1 monoclonal antibody, which completed Phase I clinical trial for treating human ErbB3; and AV-380, a potent humanized IgG1 inhibitory monoclonal antibody that is in a Phase I clinical trial for the treatment or prevention of cachexia. The company's preclinical stage product includes AV-353 that targets the Notch 3 pathway. AVEO Pharmaceuticals, Inc. has collaboration agreements with CANbridge Life Sciences Ltd.; EUSA Pharma (UK) Limited; Novartis International Pharmaceutical Ltd.; Biodesix, Inc.; St. Vincent's Hospital Sydney Limited; Biogen Idec International GmbH; Kyowa Kirin Co., Ltd.; and AstraZeneca PLC. The company was formerly known as GenPath Pharmaceuticals, Inc. and changed its name to AVEO Pharmaceuticals, Inc. in March 2005. AVEO Pharmaceuticals, Inc. was incorporated in 2001 and is headquartered in Boston, Massachusetts.
30 Winter Street
Boston, MA 02108
Boston, MA 02108
CIK: 0001325879
ISIN: US0535883070
CUSIP: 053588307
